文献速递药物相互作用药物不良反应与药物警戒

利用健康记录数据库和药代动力学模型发现并验证高维药物相互作用

Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models.
PubMed 文献 · Clin Pharmacol Ther · 2017-12-11

该研究结合流行病学与药代动力学建模,在30种常用药物中检测高维药物相互作用。通过FAERS和EMR数据库的混合药物计数响应模型,识别出增加肌病风险的多药组合,并用体外/体内外推法估算CYP450抑制。奥美拉唑、氟康唑和可乐定组合的肌病风险在FAERS中增加6.41倍,在EMR中增加18.46倍。

要点

  • 混合药物计数响应模型可跨数据库识别高维DDI信号。
  • 奥美拉唑、氟康唑和可乐定组合风险显著增高。

核心结论

  • 健康记录信息学与药代动力学建模结合是检测高维DDI的有效转化方法。

研究设计与样本

  • 结合流行病学研究与药代动力学建模,在30种常用药物中检测高维DDI。
  • 使用FAERS和EMR数据库,通过混合药物计数响应模型识别增加肌病风险的多药组合。
  • 采用体外/体内外推法估算30种药物在1至4种抑制剂存在下的CYP450抑制。

主要发现

  • 奥美拉唑、氟康唑和可乐定组合与肌病风险增加相关:FAERS中6.41倍,EMR中18.46倍,局部错误发现率<0.005。
  • 该组合中奥美拉唑的AUC比值为9.35。

临床怎么用

  • 对使用奥美拉唑、氟康唑和可乐定等高风险多药组合的患者,应警惕肌病风险并加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polypharmacy increases the risk of drug-drug interactions (DDIs). Combining epidemiological studies with pharmacokinetic modeling, we detected and evaluated high-dimensional DDIs among 30 frequent drugs. Multidrug combinations that increased the risk of myopathy were identified in the US Food and Drug Administration Adverse Event Reporting System (FAERS) and electronic medical record (EMR) databases by a mixture drug-count response model. CYP450 inhibition was estimated among the 30 drugs in the presence of 1 to 4 inhibitors using in vitro / in vivo extrapolation. Twenty-eight three-way and 43 four-way DDIs had significant myopathy risk in both databases and predicted increases in the area under the concentration-time curve ratio (AUCR) >2-fold. The high-dimensional DDI of omeprazole, fluconazole, and clonidine was associated with a 6.41-fold (FAERS) and 18.46-fold (EMR) increased risk of myopathy local false discovery rate (<0.005); the AUCR of omeprazole in this combination was 9.35. The combination of health record informatics and pharmacokinetic modeling is a powerful translational approach to detect high-dimensional DDIs.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chiang CW, Zhang P, Wang X, et al. Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models. Clin Pharmacol Ther. 2017. PMID: 29052226. doi:10.1002/cpt.914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。